" class="no-js "lang="en-US"> Visus Therapeutics Appoints Senior VP of Business and Marketing
Friday, May 24, 2024

Visus Therapeutics Appoints Ophthalmology Industry Expert Jehan Tamboowalla to Senior Vice President of Business Development and Marketing

Visus Therapeutics, a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye, today announced Jehan Tamboowalla joined the company as senior vice president of business development and marketing. At Visus, Mr. Tamboowalla will be responsible for identifying and executing strategic partnerships and collaborations as well as leading commercial activities for assets in clinical development.

“We are pleased to welcome Jehan to the Visus leadership team as we approach exciting company milestones,” said Ben Bergo, co-founder and chief executive officer at Visus Therapeutics. “Jehan’s successful record of partnering assets, acquiring novel technologies, and launching ophthalmic medicines provides Visus the expertise required to deliver on our goal of addressing critical unmet needs in the presbyopia eye drop category and beyond.”

Jehan brings over 20 years of experience in business development, marketing, and portfolio strategy in the ophthalmic and pharmaceutical spaces to Visus Therapeutics. Prior to joining Visus, he served as Vice President, Head of New Products, Ophthalmology at Novartis. At Novartis, Jehan and his team led the commercial evaluations of numerous external partnering and acquisition opportunities including, most recently, the successful acquisition of gene-therapy company, Gyroscope Therapeutics. Other notable transactions included securing global (ex-US) rights to Luxturna® from Spark Therapeutics, in-licensing Xiidra® from Takeda Pharmaceuticals, and the acquisition of the presbyopia asset, UNR844 from Encore Vision. Jehan brings a deep understanding of commercial case development and valuations having been the commercial lead on a large number of due diligences. Prior to joining Novartis, Jehan was Managing Director at Red Team Associates, a boutique consulting firm, specialized in working with emerging biopharma, private equity, and venture capital clients. Jehan’s prior industry experience includes multiple product launches and marketing roles of increasing responsibility at Bayer, Bausch & Lomb, and GSK. Jehan continues to coach and mentor future industry leaders and speak at ophthalmology industry forums on emerging innovation and commercial strategy.

“Visus is developing one of the best pipelines in the industry. I am thrilled to join Visus at such an exciting time for the company,” said Jehan. “Visus has several key milestones on the horizon, and I look forward to working closely with Ben and the entire Visus leadership team to provide effective treatments for patients impacted by vision loss.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more